BDTX: Black Diamond Therapeutics, Inc. Stock

by  •  • Comments Off on BDTX: Black Diamond Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 177.11
Enterprise Value ($M) 153.69
Book Value ($M) 97.43
Book Value / Share 1.72
Price / Book 1.82
NCAV ($M) 75.07
NCAV / Share 1.33
Price / NCAV 2.36

Profitability (mra)
Return on Invested Capital (ROIC) -0.61
Return on Assets (ROA) -0.42
Return on Equity (ROE) -0.54

Liquidity (mrq)
Quick Ratio 5.55
Current Ratio 5.55

Balance Sheet (mrq) ($M)
Current Assets 115.54
Assets 137.90
Liabilities 40.47
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G Vestal Point Capital, LP 8.90
1 day ago 13G/A T. Rowe Price Investment Management, Inc. 19.00 0.70
7 days ago 13G BlackRock, Inc. 6.20 0.00
08-08 13D/A Versant Venture Capital VI, L.P. 7.70 0.00
05-13 13D/A New Enterprise Associates 16, L.P. 8.10 31.84
05-09 13D/A Ra Capital Management, L.p. 4.95 7.65
02-13 13G/A Bb Biotech Ag 16.50 58.39

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q _______________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
2024-03-12 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ___________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 83,639 396,278 21.11
2024-11-13 51,608 305,350 16.90
2024-11-12 77,600 343,794 22.57
2024-11-11 103,911 366,008 28.39

(click for more detail)

Similar Companies
AVXL – Anavex Life Sciences Corp. BBIO – BridgeBio Pharma, Inc.
BCRX – BioCryst Pharmaceuticals, Inc. BEAM – Beam Therapeutics Inc.
BIIB – Biogen Inc.


Financial data and stock pages provided by
Fintel.io